These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38508074)

  • 1. White analytical insight for sensitive fluorescent determination of semaglutide and tirzepatide in pharmaceuticals and biological matrices.
    Mansour NM; El-Masry AA; El-Sherbiny DT; Moustafa MA
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 May; 313():124159. PubMed ID: 38508074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.
    Ding Y; Shi Y; Guan R; Yan S; Liu H; Wang Z; Li J; Wang T; Cai W; Ma G
    Pharmacol Res; 2024 Jan; 199():107031. PubMed ID: 38061595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
    Tobaiqy M; Elkout H
    Int J Clin Pharm; 2024 Apr; 46(2):488-495. PubMed ID: 38265519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirzepatide: A Review in Type 2 Diabetes.
    France NL; Syed YY
    Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
    Azuri J; Hammerman A; Aboalhasan E; Sluckis B; Arbel R
    Diabetes Obes Metab; 2023 Apr; 25(4):961-964. PubMed ID: 36507900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma.
    Imam MS; Abdelazim AH; Ramzy S; Almrasy AA; Gamal M; Batubara AS
    BMC Chem; 2023 Sep; 17(1):120. PubMed ID: 37735663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
    Vadher K; Patel H; Mody R; Levine JA; Hoog M; Cheng AY; Pantalone KM; Sapin H
    Diabetes Obes Metab; 2022 Sep; 24(9):1861-1868. PubMed ID: 35589616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Turn-On-Type Fluorescence Resonance Energy Transfer Eco-friendly Method for Nitazoxanide Quantification in Pharmaceutical Dosage Form and Spiked Plasma: Evaluation of Greenness Profile Using Different Assessment Tools.
    Mostafa EA; Elkady EF; El-Didamoony MA; Batakoushy HA
    J Fluoresc; 2023 May; 33(3):973-985. PubMed ID: 36542223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia.
    Al-Omar HA; Almodaimegh HS; Omaer A; Alzubaidi LM; Al-Harbi B; Al-Harbi I; Hassan M; Akhtar O
    J Med Econ; 2024; 27(1):418-429. PubMed ID: 38420695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.
    Goldenberg RM
    Diabetes Obes Metab; 2024 Mar; 26(3):1138-1141. PubMed ID: 38016705
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
    Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
    Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
    Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
    Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greenness assessment of micellar spectrofluorometric approach for determination of Elagolix: application to dosage form, content uniformity and human plasma.
    Ahmed RM
    Heliyon; 2021 Dec; 7(12):e08521. PubMed ID: 34934839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.
    Quddos F; Hubshman Z; Tegge A; Sane D; Marti E; Kablinger AS; Gatchalian KM; Kelly AL; DiFeliceantonio AG; Bickel WK
    Sci Rep; 2023 Nov; 13(1):20998. PubMed ID: 38017205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.
    Nicholls SJ; Tofé S; le Roux CW; D'Alessio DA; Wiese RJ; Pavo I; Brown K; Weerakkody GJ; Zeytinoglu M; Romera IC
    Cardiovasc Diabetol; 2024 Feb; 23(1):63. PubMed ID: 38341541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison.
    le Roux CW; Hankosky ER; Wang D; Malik R; Yu M; Hickey A; Kan H; Bunck MC; Stefanski A; Garcia-Perez LE; Wharton S
    Diabetes Obes Metab; 2023 Sep; 25(9):2626-2633. PubMed ID: 37344384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
    Xie Z; Hu J; Gu H; Li M; Chen J
    Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synchronous spectrofluorimetric determination of favipiravir and aspirin at the nano-gram scale in spiked human plasma; greenness evaluation.
    Batubara AS; Ainousah BE; Ramzy S; Abdelazim AH; Gamal M; Tony RM
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 Oct; 299():122880. PubMed ID: 37216820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.